Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Discourages "Negative Safety Claims" In Labels Even At The Risk Of Inconsistency

Executive Summary

FDA does not generally allow any claims in labeling that a safety issue does not exist with the product "because the evidence to support a conclusion of 'no effect' is very difficult to generate," the agency said. It's a policy that some academics say creates confusion, though.
Advertisement

Related Content

Playing It Safe: How FDA Handles Its Risk-Related Buzz Words
Gadavist Dosing Complexities To Be Handled With Packaging, Not REMS
Gadavist Dosing Complexities To Be Handled With Packaging, Not REMS
Bayer's MRI Contrast Agent Gadovist Could Get "Lower-Risk" Designation
Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS053226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel